Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity

References

• Acheampong EA, Roschel C, Mukhtar M, et al. (2009). Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. Virol J, 6, 183. doi:10.1186/1743-422X-6-183.
   PubMed Web of Science ®Google Scholar
• Alexander JJ, Anderson AJ, Barnum SR, et al. (2008). The complement cascade: yin-Yang in neuroinflammation–neuro-protection and -degeneration. J Neurochem, 107, 1169–1187.
   PubMed Web of Science ®Google Scholar
• Anesten B, Yilmaz A, Hagberg L, et al. (2016). Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurology(R) Neuroimmunol Neuroinflamm, 3, e300.
   PubMed Web of Science ®Google Scholar
• Apostolski S, McAlarney T, Hays AP, Latov N. (1994)Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1. Immunol Invest. 23(1):47–52.
   PubMed Web of Science ®Google Scholar
• Barnum SR. (2017). Complement: A primer for the coming therapeutic revolution. Pharmacol Ther;172:63–72.
   PubMed Web of Science ®Google Scholar
• Brack A, Rittner HL, Stein C. (2011). Immunosuppressive effects of opioids-clinical relevance. J Neuroimmune Pharmacol, 6, 490–502.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL. (2007). Clinical care of the HIV-infected drug user. Infect Dis Clin North Am, 21, 149–179.
   PubMed Web of Science ®Google Scholar
• Bruder C, Hagleitner M, Darlington G, et al. (2004). HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol, 40, 949–961.
   PubMed Web of Science ®Google Scholar
• Bustin SA. Quantification of mRNA using real-time reverse transcription PCR
   Google Scholar
• (RT-PCR): trends and problems. J Mol Endocrinol. 2002 Aug;29(1):23–39.
   PubMed Web of Science ®Google Scholar
• Celentano DD, Vlahov D, Cohn S, et al. (1998). Self-reported antiretroviral therapy in injection drug users. Jama, 280, 544–546.
   PubMed Web of Science ®Google Scholar
• Chong YH, Lee MJ. (2000). Expression of complement inhibitor protein CD59 in human neuronal and glial cell lines treated with HIV-1 gp41 peptides. J Neurovirol, 6, 51–60.
   PubMed Web of Science ®Google Scholar
• Datta PK, Rappaport J. (2006, Nov). HIV and complement: hijacking an immune defense. Biomed Pharmacother, 60, 561–568.
   PubMed Web of Science ®Google Scholar
• Dierich MP, Stoiber H, Clivio A. (1996). A “complement-ary” AIDS vaccine. Nat Med, 2, 153–155.
   PubMed Web of Science ®Google Scholar
• Dutta R, Roy S. (2012). Mechanism(s) involved in Opioid drug abuse modulation of HAND. Curr HIV Res, 10, 469–477.
   PubMed Web of Science ®Google Scholar
• Ellegard R, Crisci E, Andersson J, et al. (2015). Impaired NK cell activation and chemotaxis toward dendritic cells exposed to complement-opsonized HIV-1. J Immunol, 195, 1698–1704.
   PubMed Web of Science ®Google Scholar
• Elvington M, Liszewski MK, Atkinson JP. (2016). Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. Immunol Rev, 274, 9–15.
   PubMed Web of Science ®Google Scholar
• Farries TC, Atkinson JP. (1991). Evolution of the complement system. Immunol Today, 12, 295–300.
   PubMedGoogle Scholar
• Fausther-Bovendo H, Vieillard V, Sagan S, et al. (2010). HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog, 6, e1000975.
   PubMed Web of Science ®Google Scholar
• Fritzinger DC, Benjamin DE. (2016). The Complement System in Neuropathic and Postoperative Pain. Open Pain J, 9, 26–37. doi:10.2174/1876386301609010026.
   PubMedGoogle Scholar
• Gasque P, Dean YD, McGreal EP, et al. (2000). Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology, 49, 171–186.
   PubMed Web of Science ®Google Scholar
• Gasque P, Singhrao SK, Neal JW, et al. (1997). Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol, 150, 31–41.
   PubMed Web of Science ®Google Scholar
• Happel C, Steele AD, Finley MJ, et al. (2008). DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. J Leukoc Biol, 83, 956–963.
   PubMed Web of Science ®Google Scholar
• Imran M, Manzoor S, Saalim M, et al. (2016). HIV-1 and hijacking of the host immune system: the current scenario. APMIS: Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 124, 817–831.
   PubMed Web of Science ®Google Scholar
• Jacob A, Alexander JJ. (2014). Complement and blood-brain barrier integrity. Mol Immunol, 61, 149–152.
   PubMed Web of Science ®Google Scholar
• Janabi N, Peudenier S, Héron B, Ng K H, Tardieu M. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglia cells with the SV40 large T antigen. Neurosci Lett. 1995; 195:105–108.
   PubMed Web of Science ®Google Scholar
• Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, et al. (2000). Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand, 101, 116–121.
   PubMed Web of Science ®Google Scholar
• Kacani L, Stoiber H, Speth C, et al. (2001). Complement-dependent control of viral dynamics in pathogenesis of human immunodeficiency virus and simian immunodeficiency virus infection. Mol Immunol, 38, 241–247.
   PubMed Web of Science ®Google Scholar
• Krych M, Atkinson JP, Holers VM. (1992). Complement receptors. Curr Opin Immunol, 4, 8–13.
   PubMed Web of Science ®Google Scholar
• Lan J, Yang K, Byrd D, et al. (2014). Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J Immunol, 193, 3577–3589.
   PubMed Web of Science ®Google Scholar
• Letendre S. (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med, 19, 137–142.
   PubMedGoogle Scholar
• Liszewski MK, Farries TC, Lublin DM, et al. (1996). Control of the complement system. Adv Immunol, 61, 201–283.
   PubMed Web of Science ®Google Scholar
• Liu F, Dai S, Gordon J, Qin X. (2014). Complement and HIV-I infection/HIV-associatedneurocognitive disorders. J Neurovirol, 20, 184–198.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Aalinkeel R, Reynolds JL, et al. (2005a). Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res, 3, 277–288.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Parikh NU, Woodruff TM, et al. (2015). C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus. Immunology, 146, 130–143.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Schwartz SA, Aalinkeel R, et al. (2005b). Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol, 115, 323–332.
   PubMed Web of Science ®Google Scholar
• Malta M, Strathdee SA, Magnanini MM, Bastos FI. (2008). Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction, 103, 1242–1257.
   PubMed Web of Science ®Google Scholar
• Maranto J, Rappaport J, Datta PK. (2008, Mar). Regulation of complement component C3 in astrocytes by IL-1beta and morphine. J Neuroimmune Pharmacol, 3, 43–51.
   PubMed Web of Science ®Google Scholar
• Moore RD, Keruly JC, Chaisson RE. (2004). Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr, 35, 46–51.
   PubMed Web of Science ®Google Scholar
• Pace MJ, Agosto L, Graf EH, O’Doherty U. (2011). HIV reservoirs and latency models. Virology, 411, 344–354.
   PubMed Web of Science ®Google Scholar
• Posch W, Steger M, Knackmuss U, et al. (2015). Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. PLoS Pathog, 11, e1005005.
   PubMed Web of Science ®Google Scholar
• Poundstone KE, Chaisson RE, Moore RD. (2001). Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. Aids, 15, 1115–1123.
   PubMed Web of Science ®Google Scholar
• Pruenster M, Wilflingseder D, Banki Z, et al. (2005). C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol, 35, 2691–2698.
   PubMed Web of Science ®Google Scholar
• Pulanco MC, Cosman J, Ho MM, et al. (2017). Complement protein C1q enhances macrophage foam cell survival and efferocytosis. J Immunol, 198, 472–480.
   PubMed Web of Science ®Google Scholar
• Purohit V, Rapaka R, Shurtleff D. (2011). Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol, 44, 102–110.
   PubMed Web of Science ®Google Scholar
• Quigg RJ. (2002). Use of complement inhibitors in tissue injury. Trends Mol Med, 8, 430–436.
   PubMed Web of Science ®Google Scholar
• Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004 Jan 23;313(4):856–62.
   PubMed Web of Science ®Google Scholar
• Rogers CA, Gasque P, Piddlesden SJ, et al. (1996). Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology, 88, 153–161.
   PubMed Web of Science ®Google Scholar
• Roy S, Ninkovic J, Banerjee S, et al. (2011). Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol, 6, 442–465.
   PubMed Web of Science ®Google Scholar
• Rozek W, Ricardo-Dukelow M, Holloway S, et al. (2007). Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res, 6, 4189–4199.
   PubMed Web of Science ®Google Scholar
• Rozovsky I, Morgan TE, Willoughby DA, et al. (1994). Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience, 62, 741–758.
   PubMed Web of Science ®Google Scholar
• Saifuddin M, Hedayati T, Atkinson JP, et al. (1997). Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol, 78, 1907–1911.
   PubMed Web of Science ®Google Scholar
• Singh KK, Nathamu S, Adame A, et al., HIV Neurobehavioral Research Center Group. Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. (2011, May). Neurobehav HIV Med, 1, 41–52.
   Google Scholar
• Singhrao SK, Neal JW, Morgan BP, Gasque P. (1999). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp Neurol, 159, 362–376.
   PubMed Web of Science ®Google Scholar
• Speth C, Dierich MP, Sopper S. (2005). HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol, 42, 213–228.
   PubMed Web of Science ®Google Scholar
• Speth C, Schabetsberger T, Mohsenipour I, et al. (2002). Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol, 76, 3179–3188.
   PubMed Web of Science ®Google Scholar
• Speth C, Stockl G, Mohsenipour I, et al. (2001). Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol, 75, 2604–2615.
   PubMed Web of Science ®Google Scholar
• Speth C, Stoiber H, Dierich MP. (2003). Complement in different stages of HIV infection and pathogenesis. Int Arch Allergy Immunol, 130, 247–257.
   PubMed Web of Science ®Google Scholar
• Speth C, Williams K, Hagleitner M, et al. (2004). Complement synthesis and activation in the brain of SIV-infected monkeys. J Neuroimmunol, 151, 45–54.
   PubMed Web of Science ®Google Scholar
• Spudich S, Gonzalez-Scarano F. (2012). HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med, 2, a007120.
   PubMed Web of Science ®Google Scholar
• Steele AD, Henderson EE, Rogers TJ. (2003). Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology, 309, 99–107.
   PubMed Web of Science ®Google Scholar
• Stevens B, Allen NJ, Vazquez LE, et al. (2007). The classical complement cascade mediates CNS synapse elimination. Cell, 131, 1164–1178.
   PubMed Web of Science ®Google Scholar
• Strathdee SA, Palepu A, Cornelisse PG, et al. (1998). Barriers to use of free antiretroviral therapy in injection drug users. Jama, 280, 547–549.
   PubMed Web of Science ®Google Scholar
• Thomas A, Gasque P, Vaudry D, et al. (2000). Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol, 12, 1015–1023.
   PubMed Web of Science ®Google Scholar
• Ubaida-Mohien C, Lamberty B, Dickens AM, et al. (2017, Jun 19). Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. Aids, 31, 1365–1378.
   PubMed Web of Science ®Google Scholar
• Wang J, Barke RA, Charboneau R, Roy S. (2005). Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol, 174, 426–434.
   PubMed Web of Science ®Google Scholar
• Wang J, Barke RA, Charboneau R, et al. (2008). Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling. J Immunol, 180, 3594–3600.
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Rice KC, Maier SF. (2009). The “Toll” of Opioid-Induced Glial Activation: improving the Clinical Efficacy of Opioids by Targeting Glia. Trends Pharmacol Sci, 30, 581–591.
   PubMed Web of Science ®Google Scholar
• Wires ES, Alvarez D, Dobrowolski C, Wang Y, Morales M, Karn J, Harvey BK. Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J Neurovirol. 2012 Oct;18(5):400–10
   PubMed Web of Science ®Google Scholar
• Yang K, Lan J, Shepherd N, et al. (2015). Blockage of CD59 function restores activities of neutralizing and nonneutralizing antibodies in triggering antibody-dependent complement-mediated lysis of HIV-1 virions and provirus-activated latently infected cells. J Virol, 89, 9393–9406.
   PubMed Web of Science ®Google Scholar
• Yu Q, Yu R, Qin X. (2010). The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol, 7, 334–340.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ling EA, Dheen ST. (2007). Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem, 102, 667–678.
   PubMed Web of Science ®Google Scholar
• Zinyama-Gutsire RB, Chasela C, Madsen HO, et al. (2015). Role of mannose-binding lectin deficiency in HIV-1 and schistosoma infections in a rural adult population in Zimbabwe. PLoS One, 10, e0122659.
   PubMed Web of Science ®Google Scholar